
Respiratory
15 Mar 2025
Twice-Yearly Biologic Shows Long-Term Safety in Asthma
A 12-month interim analysis of the AGILE Phase III open-label extension study confirms that twice-yearly depemokimab, an ultra-long-acting anti-IL-5 biologic, maintains a favorable safety and efficacy profile in patients with type 2 asthma.

Microbiology & Infectious Diseases
15 Mar 2025
COVID-19 Booster Protection: How Long Does It Last?
Analysis of over 1.5 million U.S. adults in a new study has found that annual COVID-19 variant-targeted boosters provide meaningful protection against severe disease but lose effectiveness beyond 6 months.
Latest Journals
All JournalsCongress Reviews
All Congress ReviewsLatest Infographics
All InfographicsLatest Podcasts
All Podcasts
